# Neoadjuvant Therapy of PD-1 Blockade Combined With Chemotherapy for Esophageal Carcinoma

> **NCT05777707** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Beijing Friendship Hospital** · enrollment: 89 (estimated)

## Conditions studied

- Esophageal Carcinoma
- Neoadjuvant Immunotherapy

## Interventions

- **DRUG:** PD-1 blockade
- **DRUG:** Albumin paclitaxel
- **DRUG:** Carboplatin/Nedaplatin

## Key facts

- **NCT ID:** NCT05777707
- **Lead sponsor:** Beijing Friendship Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-10-29
- **Primary completion:** 2023-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 89 (ESTIMATED)
- **Last updated:** 2023-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05777707

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05777707, "Neoadjuvant Therapy of PD-1 Blockade Combined With Chemotherapy for Esophageal Carcinoma". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05777707. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*